Prosecution Insights
Last updated: November 04, 2026
Application No. 19/102,043

ANTIBACTERIAL COMPOUNDS

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Feb 07, 2025
Priority
Aug 10, 2022 — provisional 63/396,895 +1 more
Examiner
BRAUN, MADELINE E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Blacksmith Medicines Inc.
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
1y 11m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
105 granted / 153 resolved
+8.6% vs TC avg
Strong +25% interview lift
Without
With
+24.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
47 currently pending
Career history
196
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
26.1%
-13.9% vs TC avg
§102
16.9%
-23.1% vs TC avg
§112
38.4%
-1.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 153 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Examiner acknowledges that, according to the Filing receipt received 03/26/2026, that the instant application 19/102,043 filed 02/07/2025 is a 371 of PCT/US2023/071877 filed 08/08/2023 which claims benefit of U.S. provisional application 63/396,895 filed 08/10/2022. As such, all of the pending claims have been awarded the effective filing date of 08/10/2022. Information Disclosure Statement The Information Disclosure Statements filed on 03/21/2025, 04/16/2025, and 12/11/2025 are in compliance with the provisions of 37 CFR 1.97 and have been considered in full. A signed copy of list of references cited from the IDS is included with this Office Action. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Applicant is reminded of the proper language and format for an abstract of the disclosure. The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words in length. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, “The disclosure concerns,” “The disclosure defined by this invention,” “The disclosure describes,” etc. In addition, the form and legal phraseology often used in patent claims, such as “means” and “said,” should be avoided. The abstract of the disclosure is objected to because it contains legal phraseology ). A corrected abstract of the disclosure is required and must be presented on a separate sheet, apart from any other text. See MPEP § 608.01(b). Claim Objections Claim 42 is objected to because of the following informalities: on page 16, "substituted a bicyclic heterocycloalkyl" should read "substituted bicyclic heterocycloalkyl" and "substituted a 6-membered oxygen-containing heterocycloalkyl" should read "substituted 6-membered oxygen-containing heterocycloalky". Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 42 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 42 recites “provided that when L2 is a bond, -(C1-C6 alkylene)-, -O-, or -O-(C1-C6 alkylene)- then at least one of the following: …(iv) L2 is -O-(C1-C6 alkylene)-…”. This causes confusion as it is unclear how both can be true. It is additionally unclear if (iv) must be true if L2 is -O-(C1-C6 alkylene)-. Clarification is required. For purposes of examination, Examiner has not interpreted (iv) as a required limitation if L2 is -O-(C1-C6 alkylene)- and that one of (i)-(iii) can be true instead, since the proviso only requires “at least one” and each of (i)-(iv) are set forth as alternatives. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-2, 8-10, 17, 20, 24-25, 28, 30, 33, 40, 42, 87, 111-114, and 118 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for salts or stereoisomers, does not reasonably provide enablement for solvates. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the application coupled with information known in the art without undue experimentation. (United States v. Teletronics Inc., 8 USPQ2d 1217 (Fed. Cir. 1988)). Whether undue experimentation is needed is not based on a single factor, but rather a conclusion reached by weighing many factors (See Ex parte Forman 230 USPQ 546 (Bd. Pat. App. & Inter. 1986) and In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). These factors include the following: 1) Amount of guidance provided by applicant. The instant specification provides no species of solvates of the claimed LpxC inhibitors. The term “solvate” is incredibly broad, and in combination with the scope of the claimed compounds of Formula (I), (VI), and (XI), reads on hundreds of thousands of potential species. As was stated in Morton International Inc. v. Cardinal Chemical Co., 28 USPQ2d 1190 “The specification purports to teach, with over fifty examples, the preparation of the claimed compounds with the required connectivity. However...there is no evidence that such compounds exist...the examples of the '881 patent do not produce the postulated compounds...there is...no evidence that such compounds even exist.” The same circumstance appears to be true here. Hence, Applicants must show that solvates of these compounds can be made, or limit the claims accordingly. 2) The nature of the invention and predictability in the art. The invention is directed toward bicyclic quinone compounds. Regarding predictability in the art, chemistry is generally regarded as unpredictable, particularly the formation of solvates. Additionally see In Re Marzocchi and Horton, 169 USPQ at 367 paragraph 3: “Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why. Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor- intensive but otherwise undemanding task. In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise such work ......Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious)...” Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface. The scope of any solvates of the claimed compounds is not adequately enabled or defined. Applicants provide no guidance as to how solvates of these compounds are made. 3) Number of working examples. Applicant has provided sufficient guidance to make and use the claimed compounds, pharmaceutically acceptable salts, and stereoisomers thereof; however, the disclosure is not sufficient to allow extrapolation of the limited examples to enable the scope of the solvates thereof instantly claimed. Applicant has provided no working examples of any solvates. Within the specification, “specific operative embodiments or examples of the invention must be set forth, Examples and description should be of sufficient scope as to justify the scope of the claims, Markush claims must be provided with support in the disclosure for each member of the Markush group. Where the constitution and formula of a chemical compound is stated only as a probability or speculation, the disclosure is not sufficient to support claims identifying the compound by such composition or formula.” See MPEP 608.01(p). 4) Scope of the claims. The scope of the claims is the compounds of Formula (I), (VI), and (XI), as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Therefore, the claims are incredibly broad. 5) Level of skill in the art. The artisan using Applicant’s invention would be an individual with an M.D. or chemist with a Ph.D. degree and having several years of bench experience. 6) Undue experimentation. MPEP §2164.01 (a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." The conclusion is clearly justified here that Applicant is not enabled for making these compounds or compositions. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 42 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Teng et al. (WO 2022/173758 A1; filed Feb 2022, priority date Feb 2021; IDS filed 03/21/2025). Teng et al. discloses the following compound 13 (p. 55). PNG media_image1.png 330 478 media_image1.png Greyscale The compound is within the scope of Formula (VI) wherein R11 is methyl, R12a and R12b are hydrogen, R13 is -methylene-OH, R14 is hydrogen, v and w are 0, L2 is -O-(C1-C6 alkylene)-, and R17 is unsubstituted 6-membered oxygen containing heterocycloalkyl (see proviso (iii)). Examiner notes that, in view of the exemplary compounds on pages 99-100 and Table 2 of the instant specification, -X4-(C1-C6 alkylene)- can be read in either direction wherein X4 is bound to phenyl or C1-C6 alkylene is bound to phenyl. The applied reference has a common inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-2, 8-10, 17, 20, 24-25, 28, 30, 33, 40, 111-114, and 118 is/are rejected under 35 U.S.C. 103 as being obvious over Teng et al. (WO 2022/173758 A1; filed Feb 2022, priority date Feb 2021; IDS filed 03/21/2025) in view of Patani et al. (Chem. Rev., 1996). Teng et al. discloses compounds of Formula (I) (p. 1) wherein each R5 and R6 is independently selected from hydrogen, halogen, or C1-C4 alkyl (p. 2, first line) and t and s are 1 or 2 (p. 2, two lines before par. [0006]). PNG media_image2.png 264 398 media_image2.png Greyscale Teng et al. discloses the following species of Formula (I) (p. 53-54). PNG media_image3.png 638 1348 media_image3.png Greyscale Teng et al. discloses pharmaceutical compositions comprising the compounds of Formula (I) and a method of treating a gram-negative bacterial infection in a patient comprising administering the disclosed compounds of Formula (I), wherein the gram-negative bacterial infection is associated with Pseudomonas aeruginosa, wherein the gram-negative bacterial infection is pneumonia or a respiratory infection, wherein the patient is identified as having a lung disease (p. 7-8, pars. [0024]-[0026]). The compounds of Teng et al. differ from those of the instant invention wherein s and/or t are not 1 or 2, and at least one of R5 or R6 is not halogen, nor is the alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl of R7 substituted by at least one halogen. Teng et al. does not disclose a compound as in instant claim 40. These limitations are obvious over Patani et al. Patani et al. teaches that fluorine and hydrogen are monovalent atoms that are considered classical bioisosteres (p. 3149, col. 1). Patani et al. teaches that bioisosteres elicit similar biological activity due to common physicochemical properties (p. 3148, col. 2, par. 2). Patani et al. teaches that hydrogen and fluorine substitutions have been made in pharmacological studies in order to observe differences in properties such as affinity and activity (p. 3149, col. 2 – p. 3150, col. 1, par. 1). It would be prima facie obvious to substitute a hydrogen in the R5 or R6 position of the compounds of Teng et al. with fluorine (-F). One would have been motivated to do so, with reasonable expectation of success, as Teng et al. suggests that R5 and R6 can be halogen. Moreover, in view of Patani et al., one would be apprised that bioisosteric replacement of hydrogen with fluorine could yield different properties, such as activity, in the compounds of Teng et al. In particular, the modification of Compound 10 with one or more fluorines at R5 and/or R6 would render the following compounds of claim 40 prima facie obvious. PNG media_image4.png 338 872 media_image4.png Greyscale The applied reference has a common inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 103 might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C.102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B); or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-2, 8-10, 17, 20, 24-25, 28, 30, 33, 40, 42, 111-114, and 118 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, and 15-20 of U.S. Patent No. 12715847 B2 in view of Patani et al. (Chem. Rev., 1996). The claims of the ‘847 patent are directed toward compounds of Formula (I) wherein each R5 and R6 is independently selected from hydrogen, halogen, or C1-C4 alkyl and t and s are 1 or 2. PNG media_image5.png 184 282 media_image5.png Greyscale Claim 5 of the ‘847 patent further narrows the compounds to that of Formula (IIa) wherein R5 and R6 is independently selected from hydrogen or fluoro. Claim 15 of the ‘847 patent is directed toward compounds that are within the scope of instant claim 1 except that at least one of R5 or R6 is not halogen, nor is the alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl of R7 substituted by at least one halogen. Regarding instant claim 42, Compound 13 is within the scope of Formula (VI) wherein R11 is methyl, R12a and R12b are hydrogen, R13 is -methylene-OH, R14 is hydrogen, v and w are 0, L2 is -O-(C1-C6 alkylene)-, and R17 is unsubstituted 6-membered oxygen containing heterocycloalkyl (see instant proviso (iii)). Claim 16 of the ‘847 patent is directed toward a pharmaceutical composition of compounds of Formula (I) and a pharmaceutically acceptable excipient. Claims 17-20 of the ‘847 patent are directed toward methods of treating gram-negative and/or P. aeruginosa infection comprising administering to a patient a pharmaceutically effective amount of a compound of Formula (I), wherein the patient has been identified as having a lung disease. Patani et al. teaches that fluorine and hydrogen are monovalent atoms that are considered classical bioisosteres (p. 3149, col. 1). Patani et al. teaches that bioisosteres elicit similar biological activity due to common physicochemical properties (p. 3148, col. 2, par. 2). Patani et al. teaches that hydrogen and fluorine substitutions have been made in pharmacological studies in order to observe differences in properties such as affinity and activity (p. 3149, col. 2 – p. 3150, col. 1, par. 1). It would be prima facie obvious to substitute a hydrogen in the R5 or R6 position of the compounds of the ‘847 patent with fluorine (-F). One would have been motivated to do so, with reasonable expectation of success, as the ‘847 patent suggests that R5 and R6 can be halogen, specifically fluoro. Moreover, in view of Patani et al., one would be apprised that bioisosteric replacement of hydrogen with fluorine could yield different properties, such as activity, in the compounds of the ‘847 patent. In particular, modification of Compound 10 in claim 15 of the ‘847 patent with one or more fluorines at R5 and/or R6 would render the following compounds of claim 40 prima facie obvious. PNG media_image4.png 338 872 media_image4.png Greyscale Claims 1-2, 8-10, 17, 20, 24-25, 30, 33, 42, 111-114, and 118 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 90-92, and 136-143 of copending Application No. 19/614,234 in view of Patani et al. (Chem. Rev., 1996). Claim 1 of the ‘234 application is directed toward a compound of Formula (I). PNG media_image6.png 192 254 media_image6.png Greyscale Claims 90-92 are directed toward particular compounds, including the following. PNG media_image7.png 218 768 media_image7.png Greyscale PNG media_image8.png 208 702 media_image8.png Greyscale PNG media_image9.png 214 684 media_image9.png Greyscale PNG media_image10.png 212 294 media_image10.png Greyscale These compounds are within the scope of instant Formula (I) wherein R1 is methyl, R2a and R2b are hydrogen, R3 is -methylene-OH, R4 is hydrogen, one of R5 and R6 is hydrogen and the other is fluoro, L1 is a bond or -O-methylene-, R7 is 4- or 5-membered heterocycloalkyl, and R10 is -OH or oxo. The compounds are within the scope of Formula (VI) wherein R11 is methyl, R12a and R12b are hydrogen, R13 is -methylene-OH, R14 is hydrogen, one of R15 and R16 is hydrogen and the other is fluoro, L2 is a bond or -O-(C1-C6 alkylene)-, and R17 is sulfur-containing heterocycloalkyl or 5-membered heterocycloalkyl (see provisos (iii) and (iv)). Claim 92 additionally discloses the following compounds. PNG media_image11.png 308 352 media_image11.png Greyscale The compounds are within the scope of instant claims 1 and 33 except that at least one of R5 or R6 is not halogen, nor is the alkyl, heteroalkyl, cycloalkyl, or heterocycloalkyl of R7 substituted by at least one halogen. Claim 136 of the ‘234 application is directed toward a pharmaceutical composition of compounds of Formula (I) and a pharmaceutically acceptable excipient. Claims 137-143 of the ‘237 application are directed toward methods of treating gram-negative and/or P. aeruginosa infection comprising administering to a patient a pharmaceutically effective amount of a compound of Formula (I), wherein the patient has been identified as having a lung disease. Patani et al. teaches that fluorine and hydrogen are monovalent atoms that are considered classical bioisosteres (p. 3149, col. 1). Patani et al. teaches that bioisosteres elicit similar biological activity due to common physicochemical properties (p. 3148, col. 2, par. 2). Patani et al. teaches that hydrogen and fluorine substitutions have been made in pharmacological studies in order to observe differences in properties such as affinity and activity (p. 3149, col. 2 – p. 3150, col. 1, par. 1). It would be prima facie obvious to substitute a hydrogen in the R5 or R6 position of the compounds of claim 92 of the ‘234 application with fluorine (-F). One would have been motivated to do so, with reasonable expectation of success, as the compounds of claims 90-92 of the ‘234 application suggest that R5 and R6 can be halogen, specifically fluoro. Moreover, in view of Patani et al., one would be apprised that bioisosteric replacement of hydrogen with fluorine could yield different properties, such as activity, in the compounds of claim 92 of the ‘234 application. This is a provisional nonstatutory double patenting rejection. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MADELINE E BRAUN whose telephone number is (703)756-4533. The examiner can normally be reached M-F 8:30am-5:00pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MADELINE E BRAUN/Examiner, Art Unit 1624 10/28/2026
Read full office action

Prosecution Timeline

Feb 07, 2025
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780797
NOVEL QUINOLINE DERIVATIVE INHIBITOR
5y 8m to grant Granted Nov 03, 2026
Patent 12758543
COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA
5y 5m to grant Granted Oct 13, 2026
Patent 12758516
COMPOUNDS FOR THE TREATMENT OF NEUROPATHIC PAIN
5y 0m to grant Granted Oct 13, 2026
Patent 12741966
COMPOUNDS AND USES THEREOF
5y 2m to grant Granted Sep 22, 2026
Patent 12741955
TARGETING PLECKSTRIN-2 FOR TREATING CANCER AND OTHER DISEASES AND DISORDERS
3y 2m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
93%
With Interview (+24.8%)
3y 8m (~1y 11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 153 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month